Show simple item record

dc.contributor.authorJohansen, Pernille Palm
dc.contributor.authorZwisler, Ann Dorthe Olsen
dc.contributor.authorSvendsen, Jesper Hastrup
dc.contributor.authorFrederiksen, Marianne
dc.contributor.authorLindschou, Jane
dc.contributor.authorWinkel, Per E.R.
dc.contributor.authorGluud, Christian
dc.contributor.authorGiraldi, Annamaria G.Elena
dc.contributor.authorSteinke, Elaine E.
dc.contributor.authorJaarsma, Tiny
dc.contributor.authorKikkenborg Berg, Selina
dc.identifier.citationJohansen, Pernille Palm; Zwisler, Ann-Dorthe; Hastrup-Svendsen, Jesper; Frederiksen, Marianne; Lindschou, Jane; Winkel, Per; Gluud, Christian; Giraldi, Annamaria; Steinke, Elaine E.; Jaarsma, Tiny; Berg, Selina Kikkenborg. 2013. BMJ OPEN, vol. 3:no. 11:Article Number: e003967en_US
dc.descriptionClick on the DOI link to access the article (may not be free).en_US
dc.description.abstractIntroduction Sexuality is an important part of people’s physical and mental health. Patients with heart disease often suffer from sexual dysfunction. Sexual dysfunction has a negative impact on quality of life and well-being in persons with heart disease, and sexual dysfunction is associated with anxiety and depression. Treatment and care possibilities seem to be lacking. Studies indicate that non-pharmacological interventions such as exercise training and psychoeducation possess the potential of reducing sexual dysfunction in patients with heart disease. The CopenHeartSF trial will investigate the effect of a comprehensive sexual rehabilitation programme versus usual care. Methods and analysis CopenHeartSF is an investigator-initiated randomised clinical superiority trial with blinded outcome assessment, with 1:1 central randomisation to sexual rehabilitation plus usual care versus usual care alone. Based on sample size calculations, 154 male patients with impaired sexual function due to implantable cardioverter defibrillator or ischaemic heart disease will be included from two university hospitals in Denmark. All patients receive usual care and patients allocated to the experimental intervention group follow a 12-week sexual rehabilitation programme consisting of an individualised exercise programme and psychoeducative consultation with a specially trained nurse. The primary outcome is sexual function measured by the International Index of Erectile Function. The secondary outcome measure is psychosocial adjustment to illness by the Psychosocial Adjustment to Illness Scale, sexual domain. A number of explorative analyses will also be conducted. Ethics and dissemination CopenHeartSF is approved by the regional ethics committee (no H-4-2012-168) and the Danish Data Protection Agency (no 2007-58-0015) and is performed in accordance with good clinical practice and the Declaration of Helsinki in its latest form. Registration identifier: NCT01796353.en_US
dc.description.sponsorshipDanish Heart Foundation (no. 13-04-R95-A4669-22744); The Health Foundation (no. 2013B208); Danish Council for Strategic Research (no. 10-092790) and The Danish Nursing Council.en_US
dc.publisherBMJ Publishing Group Ltden_US
dc.relation.ispartofseriesBMJ OPEN;v.3:no.11:Article Number: e003967
dc.subjectRehabilitation medicineen_US
dc.subjectSexual medicineen_US
dc.titleThe CopenHeartSF trial-comprehensive sexual rehabilitation programme for male patients with implantable cardioverter defibrillator or ischaemic heart disease and impaired sexual function: protocol of a randomised clinical trialen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record